205 related articles for article (PubMed ID: 15936569)
21. Preclinical studies of the novel vascular disrupting agent MN-029.
Shi W; Siemann DW
Anticancer Res; 2005; 25(6B):3899-904. PubMed ID: 16309177
[TBL] [Abstract][Full Text] [Related]
22. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
23. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
24. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
25. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
Cullis ER; Kalber TL; Ashton SE; Cartwright JE; Griffiths JR; Ryan AJ; Robinson SP
Microvasc Res; 2006 Mar; 71(2):76-84. PubMed ID: 16530791
[TBL] [Abstract][Full Text] [Related]
26. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
Shi W; Siemann DW
In Vivo; 2005; 19(6):1045-50. PubMed ID: 16277020
[TBL] [Abstract][Full Text] [Related]
27. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
28. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.
Robinson SP; Howe FA; Griffiths JR; Ryan AJ; Waterton JC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):872-9. PubMed ID: 17889267
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
Beerepoot LV; Radema SA; Witteveen EO; Thomas T; Wheeler C; Kempin S; Voest EE
J Clin Oncol; 2006 Apr; 24(10):1491-8. PubMed ID: 16574998
[TBL] [Abstract][Full Text] [Related]
31. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.
McCarty MF; Takeda A; Stoeltzing O; Liu W; Fan F; Reinmuth N; Akagi M; Bucana C; Mansfield PF; Ryan A; Ellis LM
Br J Cancer; 2004 Feb; 90(3):705-11. PubMed ID: 14760388
[TBL] [Abstract][Full Text] [Related]
32. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.
Fens MH; Hill KJ; Issa J; Ashton SE; Westwood FR; Blakey DC; Storm G; Ryan AJ; Schiffelers RM
Br J Cancer; 2008 Oct; 99(8):1256-64. PubMed ID: 18797467
[TBL] [Abstract][Full Text] [Related]
33. The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.
Madhu B; Waterton JC; Griffiths JR; Ryan AJ; Robinson SP
Neoplasia; 2006 Jul; 8(7):560-7. PubMed ID: 16867218
[TBL] [Abstract][Full Text] [Related]
34. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
35. Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts.
Emoto M; Yoshihisa H; Yano K; Choijamts B; Tsugu H; Tachibana K; Aizawa M
Anticancer Res; 2015 Sep; 35(9):4757-64. PubMed ID: 26254366
[TBL] [Abstract][Full Text] [Related]
36. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
37. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
Bozec A; Lassalle S; Gugenheim J; Fischel JL; Formento P; Hofman P; Milano G
Br J Cancer; 2006 Sep; 95(6):722-8. PubMed ID: 16940984
[TBL] [Abstract][Full Text] [Related]
38. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
39. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.
Li L; Rojiani A; Siemann DW
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):899-903. PubMed ID: 9845118
[TBL] [Abstract][Full Text] [Related]
40. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
